T-cell receptor specific for influenza H5N1 peptide–major histocompatibility complex (H5N1-specific TCR)

T-cell receptors (TCRs) specific for influenza H5N1 peptide–MHC complexes are specialized immune receptors that play a pivotal role in the recognition and clearance of the highly pathogenic H5N1 avian influenza virus. These receptors, typically composed of alpha and beta chains, are expressed on the surface of T lymphocytes and are designed to identify specific viral epitopes, such as those derived from the hemagglutinin (HA) or nucleoprotein (NP), when presented by Major Histocompatibility Complex (MHC) molecules (PubMed: 20624915). Upon engagement with the peptide-MHC ligand, the TCR triggers a robust immune response characterized by the proliferation of virus-specific T cells and the targeted destruction of infected host cells. In the field of biotherapeutics, these TCRs are being isolated and cloned to develop TCR-engineered T-cell (TCR-T) therapies, which aim to provide rapid and potent cellular immunity against pandemic influenza strains (PubMed: 26865167). They also serve as critical templates for the design of next-generation vaccines that prioritize T-cell mediated protection. However, the clinical application of these TCRs faces challenges such as the high diversity of human HLA alleles and the risk of off-target cross-reactivity with endogenous human peptides.

Other names

H5N1-specific T-cell receptorInfluenza A H5N1 TCRAvian flu specific TCRTCR specific for H5N1 peptide-MHC

The T-cell receptor (TCR) recognizes and binds to specific influenza H5N1 viral peptides presented by Major Histocompatibility Complex (MHC) molecules on the surface of infected cells. This binding event triggers the TCR-CD3 complex, initiating intracellular signaling (via ITAM phosphorylation) that leads to T-cell activation, cytokine production (e.g., IFN-gamma, TNF-alpha), and the release of cytotoxic granules (perforin/granzyme) to eliminate the infected cell.